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Abstract
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by ventricular dilatation and
impaired systolic function. Patients with DCM suffer from heart failure, arrhythmia, and are at risk
of premature death. DCM has a prevalence of one case out of 2500 individuals with an incidence
of 7/100,000/year (but may be under diagnosed). In many cases the disease is inherited and is
termed familial DCM (FDC). FDC may account for 20–48% of DCM. FDC is principally caused by
genetic mutations in FDC genes that encode for cytoskeletal and sarcomeric proteins in the cardiac
myocyte. Family history analysis is an important tool for identifying families affected by FDC.
Standard criteria for evaluating FDC families have been published and the use of such criteria is
increasing. Clinical genetic testing has been developed for some FDC genes and will be increasingly
utilized for evaluating FDC families. Through the use of family screening by pedigree analysis and/
or genetic testing, it is possible to identify patients at earlier, or even presymptomatic stages of
their disease. This presents an opportunity to invoke lifestyle changes and to provide
pharmacological therapy earlier in the course of disease. Genetic counseling is used to identify
additional asymptomatic family members who are at risk of developing symptoms, allowing for
regular screening of these individuals. The management of FDC focuses on limiting the progression
of heart failure and controlling arrhythmia, and is based on currently accepted treatment guidelines
for DCM. It includes general measures (salt and fluid restriction, treatment of hypertension,
limitation of alcohol intake, control of body weight, moderate exercise) and pharmacotherapy.
Cardiac resynchronization, implantable cardioverter defibrillators and left ventricular assist devices
have progressively expanding usage. Patients with severe heart failure, severe reduction of the
functional capacity and depressed left ventricular ejection fraction have a low survival rate and may
require heart transplant.
Background
Dilated cardiomyopathy (DCM) is a disease of the heart
muscle characterized by ventricular dilatation and
impaired systolic function [1]. DCM is a leading cause of
heart failure and arrhythmia. Due to its significant preva-
lence, high mortality and morbidity, including frequent
hospitalizations, DCM is a major health concern for
adults. Despite improvements in the treatment of heart
failure introduced in the last 10 years, including the gen-
eral availability of cardiac transplantation and better med-
ical treatment, clinical outcome following the onset of
symptoms has not substantially changed. Mortality
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remains high, the disease is progressive and unrelenting,
and disability and morbidity are among the highest of any
disease or disease syndrome.
DCM is defined as idiopathic , when the disease appears
sporadic, isolated in a single member of a family and
without known cause, or familial when occurring in two or
more related family members [1,2].
Definition of DCM, diagnostic criteria of familial 
DCM and differential diagnosis
The diagnosis of DCM is made according to criteria pro-
vided by the World Health Organization/International
Society and Federation of Cardiology (WHO/ISFC) [1],
the Guidelines of the National Heart, Lung, and Blood
Institute Workshop on the Prevalence and the Etiology of
Idiopathic Dilated Cardiomyopathy [3] and the more
recent Guidelines for the Study of Familial Dilated Cardi-
omyopathies [2], designed to improve the sensitivity and
specificity of the old classification criteria.
DCM is defined by the presence of: a) fractional shorten-
ing (FS) less than 25% (> 2SD) and/or ejection fraction
less than 45% (> 2SD); and b) left ventricular end diasto-
lic diameter (LVEDD) greater than 117% (>2SD of the
predicted value of 112% corrected for age and body sur-
face area, BSA) [4], excluding any known cause of myocar-
dial disease. In the context of a familial DCM, these
criteria are used to diagnose the proband in a family.
A familial DCM (FDC) is defined by the presence of: a)
two or more affected relatives with DCM meeting the
above criteria; or b) a relative of a DCM patient with unex-
plained sudden death before the age of 35 years [2]. In
FDC, family members may be classified as affected , unaf-
fected or unknown [2]. This classification is based on major
and minor criteria that have been developed to account for
the high frequency of minor cardiac abnormalities within
families with FDC and the need of more sensitive criteria
[5,6].
In relatives, the affected status is defined by the presence
of: a) 2 major criteria consisting of left ventricular systolic
dysfunction (fractional shortening < 25% and/or ejection
fraction < 45%) and dilatation (LVEDD > 117% of the pre-
dicted value corrected for age and BSA) [4] or b) left ven-
tricular dilatation (as defined above) and  one minor
criterion; or c) 3 minor criteria. The unknown  status is
defined by the presence of 1 or 2 minor criteria and the
unaffected status is defined by the presence of a normal
heart or the determination of other causes of myocardial
dysfunction.
Minor criteria of disease are: a) unexplained supraven-
tricular arrhythmias (atrial fibrillation or sustained
arrhythmias), or frequent (> 1000/24 h) or repetitive (3 or
more ectopic beats with a heart rate > 120 beats/min) ven-
tricular arrhythmias before the age of 50; b) left ventricu-
lar dilatation (> 112% of the predicted value); c) left
ventricular dysfunction (ejection fraction < 50% or frac-
tional shortening < 28%); d) unexplained cardiac conduc-
tion system disease (grade II or III atrio-ventricular blocks,
complete left-ventricular bundle branch block, or sinus
nodal dysfunction); e) unexplained sudden death or
stroke before 50 years of age; f) segmental wall motion
abnormalities (> 1 segment, or 1 if not previously present)
in the absence of intraventricular conduction defect or
ischemic heart disease.
Exclusion criteria for idiopathic/familial DCM are: a) blood
pressure more than 160/110 mmHg, documented and
confirmed through repeated measurements; b) obstruc-
tion (more than 50%) of a major branch of the coronary
artery; c) alcohol intake more than 100 g/day; d) persist-
ent high rate supraventricular arrhythmia; e) systemic dis-
eases; f) pericardial diseases; g) congenital heart diseases;
h) cor pulmonale; j) myocarditis.
DCM can be distinguished from other forms of secondary
dilatation and dysfunction of the ventricles due to known
cardiac or systemic processes [1]. These are referred to as
secondary cardiomyopathies, named for the disease proc-
ess with which they are associated, such as ischemic cardi-
omyopathy, valvular heart cardiomyopathy, hypertensive
cardiomyopathy, alcoholic cardiomyopathy, and myocar-
ditis. Less common forms of secondary cardiomyopathies
are peripartum cardiomyopathy and cardiomyopathies
developing in the setting of amyloidosis, hemochromato-
sis, sarcoidosis, and due to toxicity from agents like doxo-
rubicin. In the pediatric population, metabolic
cardiomyopathies are encountered with greater fre-
quency. It should be noted that cases of myocarditis and
peripartum cardiomyopathy can occur in a familial set-
ting, where cases of DCM can also be present, and there-
fore, it may be difficult to classify these forms [5].
Table 1 shows the diagnostic tools available for differenti-
ating the different forms of DCM.
Epidemiology
DCM has a prevalence of one case out of 2500 individuals
[7] with an incidence of 7/100,000/year [8]. However,
DCM is probably under diagnosed and is now believed to
account for a much larger number of cases, owing to the
fact that subjects may remain asymptomatic until marked
ventricular dysfunction has occurred.
Prior to 1990, FDC was not widely recognized and genetic
contributions to the development of dilated cardiomyop-
athy were rarely implicated in disease models. In 1981, aOrphanet Journal of Rare Diseases 2006, 1:27 http://www.OJRD.com/content/1/1/27
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retrospective review of 104 patients with DCM at the
Mayo clinic estimated that approximately 2% of cases
were potentially familial in nature [9]. The paradigm
changed dramatically in 1992 when it was reported that
by carefully collecting the family history and through the
screening of relatives by physical examination and
echocardiography, 20% of cases of DCM were likely
familial [6]. More recent studies support that FDC may
account for between 35% and 48% of seemingly familial
DCM [10-13]. Unfortunately, there are no reliable clinical
or morphologic parameters able to predict the familial
form from non-genetic causes of cardiac dilatation. A
result of this circumstance is that family history data has
become critical to the evaluation of these patients and
families.
Clinical description
Patients initially present with signs and symptoms of
heart failure, due either to volume overload or to low car-
diac output. Usually, by the time of the diagnosis,
probands (here referring to the first individual diagnosed
within a family) have severe impairment of the left ven-
tricular ejection function and are in New York Heart Asso-
ciation (NYHA) functional class III-IV. Affected relatives,
on the other hand, can be asymptomatic with mild ven-
tricular dilatation and dysfunction. Twenty to thirty-five
percent of patients present with chest pain, mostly during
exercise, and the electrocardiogram (ECG) may show
pseudo-infarction Q waves. Angina pectoris is thought to
be due to limited coronary vascular reserve. Fatigue is
present in almost one third of patients. Palpitations are
very common, due to ventricular arrhythmias, neverthe-
less, syncope and sudden death rarely constitute the first
symptom of the disease. Pulmonary and systemic throm-
boembolisms occur, as first manifestation of the disease,
at a rate of 1 to 6% per year. Most of them can be found
in cases with severe left ventricular dilatation and dysfunc-
tion. A particular form of familial DCM due to mutation
of the lamin A/C gene [14,15] presents with mild dilata-
tion and severe dysfunction of the left ventricle, conduc-
tion defects, supraventricular arrhythmias, variable
skeletal muscle involvement and variable serum creatine
kinase (CPK) levels. The prognosis for many of these
patients is not favorable. X-linked FDC, due to mutations
in the dystrophin gene, has a less severe prognosis and
presents with increased CPK, muscular abnormalities, and
the typical signs of dystrophinopathy at the skeletal muscle
biopsy [16-19].
Diagnostic methods
The basic evaluation in the proband [2] consists of an
accurate family history, physical examination with spe-
cific attention to the neuromuscular apparatus, laboratory
examination including CPK, chest X-ray, ECG and
echocardiogram. In selected cases, an exercise stress test or
a pharmacological test, such as dobutamine echocardiog-
raphy, may be indicated to induce ischemia and unmask
an ischemic cardiomyopathy. More specific diagnostic
tests include hemodynamic and coronary angiographic
study, radionuclide ventriculography and endomyocar-
dial biopsy. In the presence of neuromuscular abnormal-
ities, needle skeletal muscle biopsy is indicated. Molecular
genetic diagnosis should be performed when the test is
available and may impact the clinical management. At
present, molecular genetic analysis is available for the fol-
lowing FDC genes: DES, DMD, LMNA, MYBPC3, MYH7,
TAZ, TNNT2, and TMP1. 
Etiology
In FDC, there is clear evidence of Mendelian segregation
of disease phenotype. FDC is a heterogeneous entity
(Table 2). Different forms have been identified and
Table 1: Etiology and diagnostic tools in Dilated cardiomyopathy (DCM)
Causes % of cases Diagnostic tools
Frequent 
Idiopathic/Familial DCM 20 – 50 family history, echocardiogram, detailed evaluation of first degree relatives, coronary angiography, 
endomyocardial biopsy
Ischemic DCM 50 – 70 history, coronary angiography
Valvular DCM 1.5 – 4 echocardiogram, physical exam
Hypertensive DCM 2 – 4 physical exam, echocardiogram showing hypertrophy
Alcoholic 3 – 40 history of excessive alcohol use
Myocarditis 5 – 10 history compatible with viral myocarditis, endomyocardial biopsy
Rare  2–3
Peripartum history
Amyloidosis echocardiogram, endomyocardial biopsy, rectal/fat pad biopsy
Hemochromatosis extra-cardiac signs, endomyocardial biopsy, iron studies
Sarcoidosis extra-cardiac signs, endomyocardial biopsy
Doxorubicin toxicity history of exposure to doxorubicin
Other toxic substances history
Metabolic DCM laboratory tests, pediatric ageOrphanet Journal of Rare Diseases 2006, 1:27 http://www.OJRD.com/content/1/1/27
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should be distinguished based on patterns of transmis-
sion and characteristics of the phenotype. When classifia-
ble, the clinical patterns encountered include: autosomal
dominant FDC without extracardiac manifestations; auto-
somal recessive FDC; FDC with X-linked transmission;
autosomal dominant FDC with subclinical skeletal mus-
cle involvement; autosomal dominant FDC with conduc-
tion defects; autosomal dominant left ventricular non-
compaction; unclassifiable FDC with retinitis pigmentosa
and hearing loss [5,13]. Right ventricular cardiomyopa-
thy/or arrhythmogenic right ventricular dysplasia is con-
sidered a distinct entity [1]. There is clear evidence of
incomplete penetrance as well as age-dependent pene-
trance, exemplified by the fact that FDC is typically an
Table 2: Known Familial Dilated Cardiomyopathy (FDC) genes and their OMIM references
Phenotype Frequency (%) Chromosomal 
location
Locus OMIM [40] Gene symbol Gene
Autosomal dominant FDC 56 1q32 CMD1D 191045 TNNT2  Cardiac troponin T
3p21.1 191040 TNNC1  Cardiac troponin C
2q31 CMD1G 188840 TTN  Titin
2q35 CMD1I 125660 DES  Desmin
6q12-q16 CMD1K 172405 PLN  Phospholamban
9 CMD1B 600884
10q21-q23 CMD1C 193065 VCL  Metavinculin
11p11 600958 MYBPC3  Myosin-binding protein C
11p15.1 CMD1M 600824 CSRP3  Cysteine-glycine-rich protein 3
14q11.2-13 CMD1A 160760 MYH7  Cardiac β-myosin heavy chain
15q14 CMD1A 102540 ACTC  Cardiac actin
15q22.1 191010 TPM1  α -tropomyosin
17q12 CMD1N 604488 TCAP  Tinin-cap (teletonin)
10q23.2 605906 LDB3  Cypher/ZASP
12p12.1 601439 ABCC9  Regulatory SUR2A subunit of 
cardiac KATP channel
Autosomal recessive FDC 16 19q13.42 191044 TNNI3 Cardiac troponin I
unknown 212110
X-linked DCM 10 Xp21 XLCM 300377 DMD  Dystrophin
Autosomal dominant FDC 7.7 1q11-q23 LGMD1B 150330 LMNA  Lamin A/C
with skeletal muscle disease 5q33-34 LGMD2F 601411 SGCD  δ-sarcoglycan
4q11 LGMD2E 600900 SGCB  β-sarcoglycan
6q23 CMD1F 602067
Autosomal dominant FDC 2.6 1q1-q1 CMD1A 150330 LMNA  Lamin A/C
with conduction defects 2q14-q22 CMD1H 604288
3p22.2 CMD1E 600163 SCN5A  Na channel, voltage-gated, 
type V, α polypeptide
RareFDC: 7.7
-Left ventricular non-
compaction
Xq28 300069 TAZ  G4.5 (tafazzin)
18q12.1-q12.2 601239 DTNA  α -dystrobrevin
10q23.2 605906 LDB3  Cypher/ZASP
-Autosomal recessive with 
retinitis pigmentosa and 
deafness
6q23-q24 CMD1J 605362 EYA4  Transcriptional coactivator 
EYA4
-Autosomal recessive with 
wooly hair and 
keratoderma
6p24 125647 DSP  Desmoplakin
X-linked congenital DCM Xq28 300069 TAZ  G4.5 (tafazzin)
Mitochondrial DCM mtDNA 510000Orphanet Journal of Rare Diseases 2006, 1:27 http://www.OJRD.com/content/1/1/27
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adult-onset disease and many persons carrying mutations
do not develop overt disease until their fifth or sixth dec-
ade of life [20].
Carefully designed studies of larger FDC families (by
genetic linkage analysis and other methods) have impli-
cated 29 chromosomal loci as containing FDC genes. Sev-
eral different genes at these loci have been identified to
date (Table 2). The majority of these genes encode pro-
teins that have cytoskeletal and/or contractile properties.
However, genes of the nucleoskeleton and, more recently,
ion channel encoding genes are also relevant in FDC
patients [15,21,22]. Most mutations described so far have
been private mutations and are not shared between unre-
lated families. To date, studies have primarily focused on
highly selected families and/or on relatively small num-
bers of families. Consequently, the genetic epidemiology
of mutations in FDC genes across all FDC families
remains unknown. Furthermore, as mutations have now
been described in seemingly non-familial cardiomyopa-
thies (sporadic or truly "idiopathic" DCM ), the contribution
of FDC gene mutations to isolated or sporadic dilated car-
diomyopathies is not well-defined.
Management and treatment of familial dilated 
cardiomyopathy
The management of FDC focuses on limiting the progres-
sion of heart failure and controlling arrhythmia.
General measures
They include patient education, salt and fluid restriction,
treatment of hypertension, limitation of alcohol intake,
control of body weight, and encouraging moderate exer-
cise, preferably aerobic in a controlled environment.
Pharmacological therapy
Pharmacotherapy includes a multitude of agents [23]
enclosed in the standard approaches to heart failure. Only
few of them in each class will be mentioned here.
•  Angiotensin converting enzyme (ACE) inhibitors reduce
mortality, hospitalization and progression of heart fail-
ure, as noted in several trials including CONSENSUS [24],
SOLVD [25], and SAVE [26]. These drugs are generally
started at low doses and are gradually titrated up to doses
equivalent to those showing efficacy in randomized trials.
Captopril is increased to a maximum of 50 mg three
times/day. The maximum dose of Enalapril is 20 mg
twice/day and that for Lisinopril is 40 mg once/day. The
highest tolerated doses provide the most benefit.
￿ Angiotensin receptor blockers (ARBs) provide a reasonable
alternative to ACE inhibitors (in patients who are intoler-
ant to these agents). The use of ARB is based on trials such
as ELITE-I and II [27], Val-HeFT [28], and OPTIMAAL
[29]. The dose of Losartan used in these trials was around
50 mg once/day. The maximum dose of Valsartan is 160
mg twice/day. The addition of an ARB to an ACE inhibitor
likely offers little additional benefit based on the Val-
HeFT trial.
￿ First generation calcium channel blockers are not recom-
mended in heart failure patients.
￿ Trials using endothelin antagonists have been disappoint-
ing to date and these agents are not recommend in stand-
ard guidelines [23].
￿ Diuretics have not been assessed in a randomized study
to verify their effect on survival in heart failure. Furosem-
ide is used at daily doses of 20 mg to 600 mg daily.
Bemetanide and ethacrynic acid are other loop diuretics
currently in use. Torsemide has better bioavailability
when taken orally and is used in some patients who do
not respond to oral furosemide. Frequently, the dose is
half of that of furosemide for a similar effect. When high
doses of loop diuretics are needed and, especially if the
patient has diuretic resistance, metolazone is added, usu-
ally at a dose of 2.5 mg once/day to 5 mg twice/day. Aceta-
zolamide is used at a dose of 250 to 500 mg daily in some
patients with metabolic alkalosis.
￿ Aldosterone inhibitors such as spironolactone and epler-
enone reduce mortality, as noted in RALES [30] and
EPHESUS [31], respectively. Spironolactone is used at
doses varying from 12.5 to 50 mg once/day. Eplerenone
was started with a dose of 25 mg orally once/day, which
was increased to 50 mg once/day as tolerated. Eplerenone
is more selective for the aldosterone receptor and avoids
some of the side-effects associated with spironolactone,
such as gynecomastia.
￿ Vasopressin antagonists are still under investigation.
￿ Natriuretic peptides are available only intravenously for
acute decompensation.
￿ The only inotrope, which use is widely accepted in
chronic heart failure, is digoxin. It is dosed at 0.125–0.25
mg once/day and is adjusted to renal function. A recent
post-hoc analysis of the Digitalis Investogators Group
[32] divided the patients based on their digoxin serum
level and showed that all-cause mortality was reduced by
6.3% in the subgroup of patients whose level was between
0.5 and 0.8 ng/ml.
￿ Beta-adrenergic blockers are considered a major advance
in the therapy of heart failure. CIBIS-II [33] and MERIT-
HF [34] showed a 34% relative reduction in all-cause mor-
tality using bisoprolol and metoprolol succinate (bothOrphanet Journal of Rare Diseases 2006, 1:27 http://www.OJRD.com/content/1/1/27
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beta-1 selective blockers). Carvedilol, a non-selective
beta-blocker with alpha-blocking properties reduced mor-
tality by 35% in severe heart failure (COPERNICUS) [35].
Beta-blocking agents must be titrated gradually towards
their target doses. The target dose of carvedilol is 25 mg
twice/day in patients less than 70 kg, and 50 mg twice/day
in heavier patients.
￿ The use of anticoagulants/antiplatelet agents is a controver-
sial subject and more studies are underway to identify
which therapy to use and in whom. In clinical practice,
anticoagulation is often used in patients with a left ven-
tricular ejection fraction less than 30%.
Mechanical devices
The use of cardiac resynchronization therapy (CRT) with
biventricular pacing improves symptoms in advanced
heart failure and reduces hospitalizations and mortality.
In the COMPANION trial [36] CRT reduced the risk of
death and hospitalization for any cause by approximately
20%, with a 50% reduction in the risk of death for any
cause in the subgroup of patients with non-ischemic DCM
randomized to receive CRT + defibrillator. In the treat-
ment of arrhythmias, the use of implantable cardioverter
defibrillators (ICDs) is being progressively expanded as
they are proving to be useful in reducing mortality from
sudden death compared to antiarrhythmic drugs. The
recently published SCD-HeFT trial [37] showed a 23% rel-
ative risk reduction of the primary endpoint of death from
any cause in the ICD arm compared with placebo. The use
of left ventricular assist devices (LVAD) was evaluated in
REMATCH [38]. All-cause mortality was 52% at one year
in the LVAD group versus 25% in the medical group. The
benefits of LVADs are tempered by a multitude of device-
related complications.
Finally, patients with severe heart failure, severe reduction
of the functional capacity and depressed left ventricular
ejection fraction have a low survival rate and may require
heart transplant. In this setting, heart transplantation
improves survival and quality of life.
Asymptomatic left ventricular dysfunction
So far, no trials exist on the usefulness of therapy in
asymptomatic affected relatives. However, based on stud-
ies on ischemic heart disease, it is believed that an early
use of ACE inhibitors and/or beta adrenergic blockers
could be very important in slowing the progression of the
disease.
Genetic counseling
Genetic counseling approaches for familial FDC are still
under-developed and consensus guidelines are lacking.
The high degree of genetic heterogeneity, uncertainty as to
which familial DCM genes are commonly mutated, and
the propensity to uncover private mutations, have com-
bined to hinder the development and widespread applica-
tion of clinical testing. As the disease is of relatively late
onset, many individuals in older generations may be una-
vailable for examination or may be deceased. Limited
knowledge of FDC and thorough evaluation of relatives at
risk by practicing generalists and cardiologists likely also
contributes to under-recognition of this condition.
An accurate family history and screening of first-degree
relatives has fundamental importance in FDC. This
approach is not yet widely practiced in the United States.
Each first-degree relative should undergo a detailed phys-
ical examination, ECG, and echocardiogram. Serum creat-
inine kinase levels can also be useful, especially if the
proband has elevation of this marker. Signal averaged
electrocardiography (SAECG) has also been suggested as
an additional diagnostic tool [39]. The thorough evalua-
tion of relatives of patients is standard for the research
studies of FDC.
For families where a pathogenetic mutation has been
detected, the evaluation of relatives at risk can include
molecular testing to confirm the presence or absence of
the pathologic mutation. This information can be inte-
grated into the genetic counseling provided to each indi-
vidual within that family. Non-carriers may be reassured
that they are not at increased risk of developing FDC.
Asymptomatic carriers who are at increased risk of disease
may be considered for regular evaluations (including
echocardiogram) to screen for the development of early
disease. As incomplete penetrance is a feature of this dis-
ease, the counseling session of asymptomatic mutation
carriers should focus on the increased risk of developing
FDC for mutation carriers, rather on models that implies
a certainty of disease for all mutation carriers.
In families where a pathologic mutation has not been
detected, genetic counseling is understandably less pre-
cise. A detailed examination and analysis of the pedigree
is essential to define, if possible, the likely mode of inher-
itance. Implicit in this exercise is that historical informa-
tion provided about relatives should be confirmed
through either direct evaluation of relatives or reviewing
medical records and/or autopsy reports. In performing the
genetic counseling, careful attention to the problems of
age-dependent and incomplete penetrance should be
integrated into the discussion. Relatives judged to be at
significantly increased risk of developing a cardiomyopa-
thy should be considered, as above, for regular screening.
Antenatal diagnosis
The use of molecular genetic testing to test fetuses for
adult-onset disease has been the subject of a number of
ethical discussions. In spite of initial widespread reluc-Orphanet Journal of Rare Diseases 2006, 1:27 http://www.OJRD.com/content/1/1/27
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tance to embark upon testing in this setting, a number of
recent examples are challenging this paradigm. Such dis-
cussions are likely to ensue in the context of familial DCM
once clinical genetic testing and counseling becomes
more widely available.
Unresolved questions
There are many aspects of familial DCM that remain
poorly understood. A clear and comprehensive under-
standing of the genetic epidemiology of gene mutations in
both FDC and sporadic DCM is needed. Such knowledge
will provide a foundation for the development and con-
tinued improvement of genetic testing, which will likely
be panel-based to simultaneously test multiple genes.
Animal models of FDC have been developed to better
characterize the pathogenesis of how the underlying
genetic defects initiate and/or propagate the disease proc-
ess. Ultimately, this work may suggest novel approaches
to target the underlying molecular defects. There is evi-
dence of substantial variability in phenotype within fam-
ilies, suggesting that environmental and/or modifying
genetic factors may interact with the underlying FDC
mutations. Pilot studies to explore these hypotheses are
now underway. Finally, experimental approaches to
explore how conventional cardiovascular therapies
impact the disease process are desperately needed.
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